To evaluate the role of ICOS in NDV-based immunotherapy, a combination of NDV-WT with CTLA-4 blockade was initially evaluated in ICOS-deficient mice, using a small tumour challenge for which this combination was found to be effective. Here, ICOS is linked to neoplasm.